The latest data shows that breast cancer has become the largest cancer in the world, and its incidence rate ranks first among malignant tumors. Its 5-year survival rate of breast cancer is nearly 90%, essentially similar to the management of chronic diseases. On December 13, 2023, the National Health Insurance Bureau announced the results of the adjustment of the national health insurance directory in 2023. A total of 126 drugs were added to the national health insurance drug directory, of which the first monoclonal antibody subcutaneous preparation (trastuzumab injection "subcutaneous preparation") for the treatment of breast cancer was also included in the new health insurance directory, helping breast cancer enter the era of chronic disease management, and bringing new treatment hopes and new treatment models to the majority of breast cancer patients. Recently, in order to improve the public's awareness of the era of chronic disease management of breast cancer, our reporters have conducted in-depth online and offline exchanges and discussions with clinical experts on hot topics of breast cancer prevention and treatment. Medical experts from Guangzhou, Foshan, Yangjiang, Zhongshan, Heyuan, Shantou, Chaozhou, Jieyang and other places participated in this science popularization activity. Interview experts: Chen Kai, Chen Tao, Fang Zhichao. Experts: Chen Kai, Chief Physician of Sun Yixian Memorial Hospital of Sun Yat sen University, Master Supervisor Experts: Fang Zhichao, Vice President of Chaozhou People's Hospital, Director of Breast Prevention and Control Center Experts: Chen Tao, Deputy Chief Physician of Breast Center of Chaozhou People's Hospital, Deputy Chief Physician of breast cancer Incidence Trend and Prevention Latest data show that breast cancer has become the largest cancer in the world, with incidence rate ranking first among malignant tumors, and its five-year survival rate of breast cancer is nearly 90%, essentially similar to the management of chronic diseases. Professor Chen Kai: "breast cancer is the malignant tumor with the highest incidence rate among women, and there is a clear trend of being younger. With the incidence rate getting higher and younger, the patients' demand for treatment of breast cancer is also increasing. For example, for surgery, the demand for less invasive surgery is increasing. Especially for young patients, cutting off the breast is a great psychological trauma, which will affect her return to society. In addition, the demand for the beauty of the breast is also increasing." Professor Chen Tao: "Now breast cancer has entered the era of slow disease management. Before we all knew that cancer may not be long lived. Now we can still live for a long time. Including lung cancer, breast cancer, etc. The 2016 China Health 2030 Plan outlines that by 2030 we will achieve the full life cycle chronic disease health management of the whole population. The overall five-year survival rate of cancer should be increased by 15%. breast cancer is about 420000 new cases in China every year." Professor Fang Zhichao: "For breast cancer, we should pay attention to high-risk groups as soon as possible. It is suggested that women with family history should have regular physical examination after the age of 40. For basic tumors, we should screen them through the diagnosis of a specialist to confirm whether they are breast cancer as soon as possible. Ten year survival of early breast cancer has reached more than 90%. Early detection and early treatment is the key to improving the overall survival and prognosis of breast cancer." What breast cancer treatment drugs are included in this year's medical insurance catalog? What is its significance and value? Professor Fang Zhichao: "With the standardization of breast cancer treatment, new drugs are emerging according to different molecular types